Select Publications

1: Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Res Commun. 2022 Jul 1;2(7):570-576. doi: 10.1158/2767-9764.CRC-22-0028. PMID: 36923283; PMCID: PMC10010328.

2: Tsang ES, Munster PN. Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead. Onco Targets Ther. 2022 Dec 13;15:1509-1518. doi: 10.2147/OTT.S322297. PMID: 36536949; PMCID: PMC9758980.

3: Munster PN, Greenstein AE, Fleming GF, Borazanci E, Sharma MR, Custodio JM, Tudor IC, Pashova HI, Shepherd SP, Grauer A, Sachdev JC. Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Clin Cancer Res. 2022 Aug 2;28(15):3214-3224. doi: 10.1158/1078-0432.CCR-21-4363. PMID: 35583817; PMCID: PMC9662918.

4: Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 2020 Jul 17;11(1):3584. doi: 10.1038/s41467-020-17414-y. PMID: 32681091; PMCID: PMC7367885.

5: Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G Jr, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC. First- In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag Res. 2019 Dec 13;11:10463-10476. doi: 10.2147/CMAR.S208720. PMID: 31853198; PMCID: PMC6916675.

6: Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019 Aug 1;5(8):1141-1149. doi: 10.1001/jamaoncol.2019.1048. PMID: 31194228; PMCID: PMC6567832.

7: Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019 Jun 11;73(22):2859-2868. doi: 10.1016/j.jacc.2019.03.495. PMID: 31171092; PMCID: PMC6557296.

8: Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. Clin Cancer Res. 2019 Aug 15;25(16):4917-4923. doi: 10.1158/1078-0432.CCR-19-0171. Epub 2019 May 31. PMID: 31152020.

9: Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Molnár I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Br J Cancer. 2018 Oct;119(9):1086-1093. doi: 10.1038/s41416-018-0235-2. Epub 2018 Oct 26. PMID: 30361524; PMCID: PMC6219487.

10: Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018 Jul 1;29(7):1561-1568. doi: 10.1093/annonc/mdy171. PMID: 29726923.

11: Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget. 2017 Dec 12;8(69):114156-114172. doi: 10.18632/oncotarget.23169. PMID: 29371976; PMCID: PMC5768393.

12: Park J, Thomas S, Zhong AY, Wolfe AR, Krings G, Terranova-Barberio M, Pawlowska N, Benet LZ, Munster PN. Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer. Sci Rep. 2018 Jan 8;8(1):92. doi: 10.1038/s41598-017-18436-1. PMID: 29311658; PMCID: PMC5758798.

13: Terranova-Barberio M, Thomas S, Munster PN. Host histone acetylation unlocks HDAC inhibitor potential. Oncotarget. 2017 Nov 13;8(63):106161-106162. doi: 10.18632/oncotarget.22422. PMID: 29290932; PMCID: PMC5739717.

14: Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11;19(1):107. doi: 10.1186/s13058-017-0896-4. PMID: 28893315; PMCID: PMC5594551.

15: Thomas S, Chen S, Sbitany H, Kwon E, Piper M, Park J, Terranova Barberio M, Pawlowska N, Munster PN. Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer. Plast Reconstr Surg. 2017 Sep;140(3):537-544. doi: 10.1097/PRS.0000000000003579. PMID: 28841614; PMCID: PMC5604844.

16: Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 1;23(21):6400-6410. doi: 10.1158/1078-0432.CCR-17-0703. Epub 2017 Aug 8. Erratum in: Clin Cancer Res. 2018 Feb 15;24(4):985. PMID: 28790114.

17: Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol. 2017 Apr 10;35(11):1231-1239. doi: 10.1200/JCO.2016.70.5350. Epub 2017 Feb 21. PMID: 28221861; PMCID: PMC5791833.

18: Munster PN. Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome. JAMA Oncol. 2016 Aug 1;2(8):1089-90. doi: 10.1001/jamaoncol.2016.0614. PMID: 27228206.

19: Terranova-Barberio M, Thomas S, Munster PN. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy. 2016 Jun;8(6):705-19. doi: 10.2217/imt-2016-0014. PMID: 27197539; PMCID: PMC5705793.

20: Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016 May;27(5):947-52. doi: 10.1093/annonc/mdw044. Epub 2016 Feb 21. PMID: 26903311; PMCID: PMC4843187.

21: Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb;155(3):521-30. doi: 10.1007/s10549-016-3701-7. Epub 2016 Feb 13. PMID: 26875185.

22: Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15;22(8):1932-9. doi: 10.1158/1078-0432.CCR-15-1665. Epub 2015 Nov 24. PMID: 26603258.

23: Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 1;121(19):3481-90. doi: 10.1002/cncr.29422. Epub 2015 Jul 15. PMID: 26177599; PMCID: PMC4832308.

24: Park J, Thomas S, Munster PN. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Epigenomics. 2015;7(4):641-52. doi: 10.2217/epi.15.16. PMID: 26111034.

25: Munster PN. More Options for Fertility Preservation for Patients With Cancer. J Clin Oncol. 2015 Aug 1;33(22):2413-5. doi: 10.1200/JCO.2015.61.9304. Epub 2015 Jun 22. PMID: 26101241.

26: Oktay K, Rodriguez-Wallberg K, Munster P. Ovarian protection during adjuvant chemotherapy. N Engl J Med. 2015 Jun 4;372(23):2268-9. doi: 10.1056/NEJMc1504241. PMID: 26039611.

27: Raha P, Thomas S, Thurn KT, Park J, Munster PN. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015 Feb 25;17(1):26. doi: 10.1186/s13058-015-0533-z. PMID: 25848915; PMCID: PMC4367983.

28: Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015 Mar 20;33(9):1060-6. doi: 10.1200/JCO.2014.57.5027. Epub 2015 Jan 20. PMID: 25605849.

29: Aggarwal R, Grabowsky J, Strait N, Cockerill A, Munster P. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies. Cancer Chemother Pharmacol. 2014 Aug;74(2):359-65. doi: 10.1007/s00280-014-2510-0. Epub 2014 Jun 17. PMID: 24934865; PMCID: PMC5257275.

30: Zhang X, Munster PN. New protein kinase inhibitors in breast cancer: afatinib and neratinib. Expert Opin Pharmacother. 2014 Jun;15(9):1277-88. doi: 10.1517/14656566.2014.913570. Epub 2014 Apr 30. PMID: 24787047.

31: Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN. Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther. 2013 Oct;12(10):2078-87. doi: 10.1158/1535-7163.MCT-12-1242. Epub 2013 Aug 12. PMID: 23939379; PMCID: PMC3821775.

32: Munster PN. Fertility preservation and breast cancer: A complex problem. Oncology (Williston Park). 2013 Jun;27(6):533-9. PMID: 23909066.

33: Thomas S, Thurn KT, Raha P, Chen S, Munster PN. Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. PLoS One. 2013 Jul 9;8(7):e68973. doi: 10.1371/journal.pone.0068973. PMID: 23874830; PMCID: PMC3711340.

34: Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012 Feb 10;30(5):533-8. doi: 10.1200/JCO.2011.34.6890. Epub 2012 Jan 9. PMID: 22231041; PMCID: PMC3295555.

35: Raha P, Thomas S, Munster PN. Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics. 2011 Aug;3(4):451-70. doi: 10.2217/epi.11.72. PMID: 22126205.

36: Munster PN, Daud AI. Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Expert Opin Investig Drugs. 2011 Nov;20(11):1565-74. doi: 10.1517/13543784.2011.617740. PMID: 21985236.

37: Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 7;104(12):1828-35. doi: 10.1038/bjc.2011.156. Epub 2011 May 10. PMID: 21559012; PMCID: PMC3111195.

38: Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 2011 Feb;7(2):263-83. doi: 10.2217/fon.11.2. PMID: 21345145; PMCID: PMC3127396.

39: Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat. 2011 Nov;130(2):437-47. doi: 10.1007/s10549-011-1364-y. Epub 2011 Feb 5. PMID: 21298336; PMCID: PMC3760725.

40: Munster PN, Rubin EH, Van Belle S, Friedman E, Patterson JK, Van Dyck K, Li X, Comisar W, Chodakewitz JA, Wagner JA, Iwamoto M. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res. 2009 Nov 15;15(22):7077-84. doi: 10.1158/1078-0432.CCR-09-1214. Epub 2009 Nov 3. PMID: 19887475.

41: Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer. 2009 Oct 6;101(7):1044-50. doi: 10.1038/sj.bjc.6605293. Epub 2009 Sep 8. PMID: 19738609; PMCID: PMC2768109.

42: Munster PN, Carpenter JT. Estradiol in breast cancer treatment: reviving the past. JAMA. 2009 Aug 19;302(7):797-8. doi: 10.1001/jama.2009.1223. PMID: 19690316.

43: Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther. 2009 Apr;8(4):794-801. doi: 10.1158/1535-7163.MCT-08-0985. PMID: 19372552.

44: Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 2009 Apr 1;15(7):2488-96. doi: 10.1158/1078-0432.CCR-08-1930. Epub 2009 Mar 24. PMID: 19318486.

45: Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA 3rd, Lush R, Neuger A, Sullivan DM, Munster PN. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res. 2009 Apr 1;15(7):2479-87. doi: 10.1158/1078-0432.CCR-08-1931. Epub 2009 Mar 24. PMID: 19318485.

46: Thomas S, Munster PN. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett. 2009 Aug 8;280(2):184-91. doi: 10.1016/j.canlet.2008.12.026. Epub 2009 Jan 30. PMID: 19185986.

47: Biçaku E, Marchion DC, Schmitt ML, Münster PN. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res. 2008 Mar 1;68(5):1513-9. doi: 10.1158/0008-5472.CAN-07-2822. PMID: 18316616.

48: Marchion D, Münster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. doi: 10.1586/14737140.7.4.583. PMID: 17428177.

49: Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther. 2005 Dec;4(12):1993-2000. doi: 10.1158/1535-7163.MCT-05-0194. PMID: 16373714.

50: Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res. 2005 Dec 1;11(23):8467-75. doi: 10.1158/1078-0432.CCR-05-1073. PMID: 16322310.

51: Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 2005 May 1;65(9):3815-22. doi: 10.1158/0008-5472.CAN-04-2478. PMID: 15867379.

52: Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Sequence- specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem. 2004 May 15;92(2):223-37. doi: 10.1002/jcb.20045. PMID: 15108350.